Prognostic significance of Dickkopf-1 in head and neck squamous cell carcinoma.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2024-03-01 Epub Date: 2023-12-05 DOI:10.1080/14737140.2023.2289597

Kai Chen, Jin Li, Yanfeng Ouyang, Yulong Xie, Guiqiong Xu, Tianliang Xia, Rui You, Guichao Liu, Han He, Rong Huang, Mingyuan Chen

{"title":"Prognostic significance of Dickkopf-1 in head and neck squamous cell carcinoma.","authors":"Kai Chen, Jin Li, Yanfeng Ouyang, Yulong Xie, Guiqiong Xu, Tianliang Xia, Rui You, Guichao Liu, Han He, Rong Huang, Mingyuan Chen","doi":"10.1080/14737140.2023.2289597","DOIUrl":null,"url":null,"abstract":"Background: Dickkopf-1 (DKK1) exhibits abnormal expression in various cancers and correlates with poor prognosis. This study investigates DKK1's prognostic relevance in head and neck squamous cell carcinoma (HNSC).Methods: We conducted a comprehensive search across literature and sequencing databases to gather eligible studies and HNSC datasets. We calculated pooled standardized mean differences (SMD) and 95% confidence intervals (CI) for clinical characteristics, as well as hazard ratios (HR) with 95% CIs for overall survival (OS) and progression-free/disease-free survival (PFS/DFS). Sensitivity analysis gauged result stability, and Egger's test assessed publication bias.Results: Pooled results indicated that HNSC patients with higher T-stage exhibited elevated DKK1 expression levels, and this elevated expression was associated with shorter OS and PFS/DFS. While sensitivity analysis identified some studies significantly affecting pooled results, most were unaffected, and no publication bias was detected.Conclusion: DKK1 holds promise as a potential biomarker for predicting poor prognosis in HNSC patients, but further research is needed for confirmation.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2289597","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Dickkopf-1 (DKK1) exhibits abnormal expression in various cancers and correlates with poor prognosis. This study investigates DKK1's prognostic relevance in head and neck squamous cell carcinoma (HNSC).

Methods: We conducted a comprehensive search across literature and sequencing databases to gather eligible studies and HNSC datasets. We calculated pooled standardized mean differences (SMD) and 95% confidence intervals (CI) for clinical characteristics, as well as hazard ratios (HR) with 95% CIs for overall survival (OS) and progression-free/disease-free survival (PFS/DFS). Sensitivity analysis gauged result stability, and Egger's test assessed publication bias.

Results: Pooled results indicated that HNSC patients with higher T-stage exhibited elevated DKK1 expression levels, and this elevated expression was associated with shorter OS and PFS/DFS. While sensitivity analysis identified some studies significantly affecting pooled results, most were unaffected, and no publication bias was detected.

Conclusion: DKK1 holds promise as a potential biomarker for predicting poor prognosis in HNSC patients, but further research is needed for confirmation.

查看原文本刊更多论文

Dickkopf-1在头颈部鳞状细胞癌中的预后意义。

背景:Dickkopf-1 (DKK1)在多种癌症中表现出异常表达，并与不良预后相关。本研究探讨DKK1与头颈部鳞状细胞癌(HNSC)预后的相关性。方法:我们对文献和测序数据库进行了全面的检索，以收集符合条件的研究和HNSC数据集。我们计算了临床特征的标准化平均差异(SMD)和95%置信区间(CI)，以及总生存期(OS)和无进展/无病生存期(PFS/DFS)的风险比(HR)和95% CI。敏感性分析评估结果的稳定性，Egger检验评估发表偏倚。结果:综合结果表明，t期较高的HNSC患者DKK1表达水平升高，且这种表达升高与较短的OS和PFS/DFS相关。虽然敏感性分析发现一些研究显著影响汇总结果，但大多数研究未受影响，未发现发表偏倚。结论:DKK1有望作为预测HNSC患者预后不良的潜在生物标志物，但需要进一步的研究来证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.